<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767607</url>
  </required_header>
  <id_info>
    <org_study_id>GFY202001</org_study_id>
    <nct_id>NCT04767607</nct_id>
  </id_info>
  <brief_title>Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy</brief_title>
  <official_title>International Peace Maternity and Child Health Hospital (IPMCH) Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Peace Maternity and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>School of Biomedical Engineering, Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International Peace Maternity and Child Health Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to predict the ovarian reserve, especially premature ovarian&#xD;
      insufficient (POI), in young breast cancer patients during chemotherapy treatment using&#xD;
      ultrasensitive anti-Müllerian hormone (AMH) detection method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Young breast cancer women are often treated with adjuvant chemotherapy and neoadjuvant&#xD;
      chemotherapy regiments include cyclophosphamide, anthracyclines and a taxane. These&#xD;
      treatments can adversely affect ovarian function across the lifespan, causing premature&#xD;
      menopause, infertility, and POI. AMH is currently the most robust marker of prediction of&#xD;
      ovarian injury in cancer patients during chemotherapy in compare with other sexual hormone&#xD;
      marker (such as follicle stimulating hormone (FSH), inhibin B) and ovarian volume, and is a&#xD;
      more convenient way of prediction of ovarian reserve compare antral follicle count (AFC). But&#xD;
      most of the patients' AMH levels become undetectable (using common AMH kits) after several&#xD;
      cycle of chemotherapy, and some of these patients' AMH levels will maintained at a low level&#xD;
      after chemotherapy, while others will recover. Using the ultrasensitive AMH detection method&#xD;
      is expected to accurately assess the ovarian reserve during the chemotherapy treatment,&#xD;
      predicting the risk of ovarian failure, and providing patients with ovarian and fertility&#xD;
      function protection recommendations, such as using GnRHa regents during treatment and&#xD;
      providing assisted reproductive technology consultants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the trend of anti-Müllerian hormone (AMH) level at chemotherapy process and post-chemotherapy in breast cancer patients.</measure>
    <time_frame>1 year.</time_frame>
    <description>Serum anti-Müllerian hormone (AMH) concentration can be measured on any day during the menstrual cycle. Serum AMH will be measured at each chemotherapy administration and 1 year post-chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the trend of Follicle-Stimulating Hormone (FSH) level at chemotherapy process and post-chemotherapy in breast cancer patients.</measure>
    <time_frame>1 year.</time_frame>
    <description>Serm FSH concentration will be measured at each chemotherapy process and 1 year post-chemotherapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with chemotherapy-induced amenorrhoea/oligomenorrhea and recovery rate of menses during chemotherapy process and 1 year post-chemotherapy treatment.</measure>
    <time_frame>1 year.</time_frame>
    <description>Disappearance and reappearance of two consecutive menstrual periods within 21 to 35 days during chemotherapy treatment and 1 year post-chemotherapy.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer plus chemotherapy</arm_group_label>
    <description>Patients of the group will receive chemotherapy treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer without chemotherapy</arm_group_label>
    <description>Patients of the group will not receive chemotherapy treatment.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serm&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        200 premenopausal breast cancer female patients of age 18-50 treated in the International&#xD;
        Peace Maternity and Child Health Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female 18-50 years.&#xD;
&#xD;
          2. Suffering from breast cancer.&#xD;
&#xD;
          3. Treated with adjuvant or neoadjuvant chemotherapy.&#xD;
&#xD;
          4. Having regular menstrual cycle before chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bilateral oophorectomy or ovarian irradiation before enrollment.&#xD;
&#xD;
          2. Prior chemotherapy.&#xD;
&#xD;
          3. Oral contraceptives before enrollment.&#xD;
&#xD;
          4. Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongmei Lai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongmei Lai, M.D.</last_name>
    <phone>86-021-64070434</phone>
    <phone_ext>27721</phone_ext>
    <email>laidongmei@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The International Peace Maternity and Child Health Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongmei Lai, M.D</last_name>
      <phone>86-21-64070434-27701</phone>
      <email>laidongmei@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dezellus A, Barriere P, Campone M, Lemanski C, Vanlemmens L, Mignot L, Delozier T, Levy C, Bendavid C, Debled M, Bachelot T, Jouannaud C, Loustalot C, Mouret-Reynier MA, Gallais-Umbert A, Masson D, Freour T. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017 Jul;79:72-80. doi: 10.1016/j.ejca.2017.03.035. Epub 2017 Apr 29.</citation>
    <PMID>28463758</PMID>
  </reference>
  <reference>
    <citation>Fréour T, Barrière P, Masson D. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer. 2017 Mar;74:1-8. doi: 10.1016/j.ejca.2016.12.008. Epub 2017 Jan 28. Review.</citation>
    <PMID>28135602</PMID>
  </reference>
  <reference>
    <citation>Lie Fong S, Lugtenburg PJ, Schipper I, Themmen AP, de Jong FH, Sonneveld P, Laven JS. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod. 2008 Mar;23(3):674-8. doi: 10.1093/humrep/dem392. Epub 2008 Jan 23.</citation>
    <PMID>18216040</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>International Peace Maternity and Child Health Hospital</investigator_affiliation>
    <investigator_full_name>Dongmei Lai</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>ovarian reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The public can require the data and protocol from clinicaltrials.gov posted by investigator.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>2 years</ipd_time_frame>
    <ipd_access_criteria>Public</ipd_access_criteria>
    <ipd_url>http://clinicaltrials.gov</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

